OSCI previews 4th quarter revenue, which is towards the high end of the analysts' range, and well above the average of about $8.3 million.
>>WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 9, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI - News) today disclosed preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2005. The Company expects to record total fourth quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE® (gemifloxacin mesylate) tablets, and the remainder primarily from the Company's co-promotion partnership for TESTIM®1% testosterone gel. The Company plans to announce complete audited financial results and host a conference call with investors on March 6, 2006.
"FACTIVE ended the year strongly, with revenues up more than 60 percent from the third quarter of 2005, and nearly triple the levels generated in the fourth quarter of 2004," stated Steven M. Rauscher, President and Chief Executive Officer of Oscient Pharmaceuticals. "As the respiratory tract infection season continues to build toward its peak, the weekly prescription total for FACTIVE recently surpassed 7,000 per week, a high for our sales team."
During the fourth quarter nearly 70,000 prescriptions were written - more than three times the total in the fourth quarter of 2004. To date, approximately 230,000 prescriptions for FACTIVE have been written by over 18,000 physicians. FACTIVE was launched in September 2004 and is currently promoted to primary care physicians by 300 sales representatives in the United States.
For the full fiscal year of 2005, the Company expects to record approximately $23 million in total revenues, with approximately $20 million in revenue from FACTIVE. Oscient expects total cash, restricted cash and investments balance at year-end to be approximately $80 million.<<
snip
Cheers, Tuck |
